Objective: To develop a novel and potent fusion inhibitor of HIV infection based on a rational strategy for synthetic antibody library construction.
Introduction
Significant advances in antiretroviral therapy have occurred as the approval of the first fusion inhibitor, T-20 [1] . T-20 peptide derives from the C-terminal region (HR2) of gp41 fusion protein from HIV [2, 3] . By competitively binding the N-terminal region (HR1), T-20 impairs HR1-HR2 interaction [2] and consequently the formation of the six-helix bundle (6HB) structure, responsible for HIV fusion (reviewed in Wilen et al. [4] ). Despite the well characterized antiviral potency of T-20, clinical resistance has been reported in HIV-1-infected patients [5] . Additionally, T-20 is described as antigenic [6] , highly expensive, protease-susceptible (no oral administration), and 'pharmacokinetically limited', among other limitations [7] . Overall, development of novel HIV fusion inhibitors with improved biophysical and pharmacokinetic properties is required.
Antibody fragments emerged to overcome issues associated with high-molecular weight of native antibody structure (IgG), mainly the targeting of cryptic epitopes and the penetration into densely packed tissues. Single-domain antibody (sdAb) is currently the smallest functional antibody fragment, only constituted by the antibody heavy-chain or light-chain variable domains (VH or VL) [8] . Additionally to the reduced size, complementarydetermining regions (CDRs; antigen-binding regions) of dAbs can be easily engineered to develop specific and highaffinity binders. sdAbs also present excellent biophysical properties, such as high stability, solubility, and low toxicity [9] . Despite these beneficial features, only the therapeutic potential of VH domains have been intensively explored [10] . Nevertheless, several reports have demonstrated that VL domains present excellent biophysical properties, such as high expression yield, resistance to aggregation and proteases, stability, and high reversibility of thermal unfolding, in some cases better than VHs [11] [12] [13] [14] . Moreover, the stability of VL domains was further evidenced by the proved functionality of these dAbs in the absence of disulfide bonds [15, 16] or in the reducing cellular environment [17, 18] .
Here, we engineered a VL sdAb with elongated CDRs that broadly and potently inhibits HIV-1 infection by targeting a well conserved and crucial-to-fusion sequence on HR1. Despite the clinical resistance to HR1-targeting T-20, this region contains highly conserved residues among HIV-1 subtypes and isolates [19] , representing a major target to HIV infection impairment. Anti-HR1 VLs were selected by phage display technology from a restricted combinatorial library. Epitope mapping of the two most potent antiviral VLs -selected against an HIV-1 laboratory-adapted strain -showed that these inhibitors target a highly conserved and critic region within HR1. One VL (F63) showed high potency to inhibit HIV-1 and HIV-2 primary isolates with comparable T-20 activity. For last, we demonstrated that F63 also interacts with lipid membranes, a key ability of potent HIV entry inhibitors [20, 21] that correlates with their mechanism of action.
Methods

Inhibition assays
HIV-1 laboratory-adapted strain NL4-3 (HIV-1 NL4-3 ) production was performed as described [22] and 50% tissue culture infectious dose determined as Borrego et al. [6] . HIV-2 and HIV-1 primary isolates from subtypes J and H were obtained from Borrego et al. [6] . HIV-1 variant NL4-3 D36G (parental) and HIV-1 variants resistant to T-20 NL4-3 (D36G) V38A/N42D and V38A/N42T (NIH AIDS Reagent Program) were propagated accordingly to Borrego et al. [6] . HIV-1 primary isolates from subtypes B and C were obtained from Calado et al. [23] .
For all the inhibition assays, viruses or HeLa243env/ HeLa273Denv cells were incubated with titrated amounts of the inhibitors during 1 h at 378C prior to infection and HIV infectivity was measured 48 h postinfection. In Jurkat E6-1 (NIH AIDS Reagent Program) inhibition assay, HIV p24 CA concentrations were measured by ELISA (NCI, Frederick, Maryland, USA) according to manufacturer's instructions. In inhibition assays with TZM-bl cells (NIH AIDS Reagent Program) [6] , luciferase or 'b-galactosidase' expression was quantified with the One-Glow luciferase assay substrate reagent (Promega, USA) according to manufacturer's instructions or as described in Da Silva et al. [24] , respectively. Cellcell fusion assay was adapted from Schwartz et al. [25] . HeLa243env or HeLa273Denv cells [25] were cocultured at a 1 : 1 ration with multinuclear activation of a galactosidase indicator (MAGI) cells (NIH AIDS Reagent Program) in the presence of inhibitors. After 48 h, 'b-galactosidase' expression was quantified as described [24] . Peripheral blood mononuclear cells' isolation, maintenance, and inhibition assays were performed as previously described [23] with the following exception: at 7 days postinfection, HIV p24 CA concentrations were measured by ELISA. The 50% inhibitory concentration (IC 50 ) estimation and statistical analysis were performed as described [6, 26] .
The remaining experimental procedures are provided in the Supplementary Methods (http://links.lww.com/ QAD/A912).
Results
Selection of anti-HIV VLs with elongated complementary-determining region 1 and complementary-determining region 3
In contrast to regular binding regions, long and flexible CDR3 of camelid heavy-chain antibodies [27] can successfully target hidden and nonstandard (immuneevasion) epitopes [9, 28] . We proposed to translate these CDR features to a noncamelid scaffold -a rabbit k VL domain [29] derived from a previously selected singlechain variable fragment [30] . In addition to the stability already attributed to VL sdAbs [11] [12] [13] [14] , their solubility seems less affected by sequence variation in CDRs than VH domains [14] . We chose a nonhuman domain because of the extensive CDR3 length heterogeneity naturally present in the k light chains of rabbit antibodies, in contrast with human ones [31, 32] . Furthermore, this particular VL domain was shown to be highly stable and soluble in the absence of its counterpart VH domain [29] . The naturally longer and most exposed CDR of parental VL (CDR3; Fig. S1A , http://links.lww.com/QAD/ A912), hereafter named VL parental , was grafted with a series of long CDRs containing a well characterized paratope for hen egg-white lysozyme [33] flanked by sequences of serines/glycines. These small amino acids -major contributors to conformational flexibility of antibody CDRs [34, 35] -were added to elongate the original CDR3 of 11 amino acids to 22, 26, or 30 amino acids ( Fig. S1B , http://links.lww.com/QAD/A912). Evaluation of VL parental functionality in the presence of an elongated CDR3 is presented in Supplementary Information.
After validation of VL parental functionality in the presence of an elongated CDR3, we used it as a scaffold for synthetic library construction. This library was designed to select anti-HIV minimal antibody fragments with high-affinity toward a cryptic HR1 region. We chose to elongate both CDR1 and CDR3 to increase theoretically the affinity of the selected dAbs and at the same time avoid unspecific binding from the original CDR1. For the CDRs library construction, we used the previously validated strategy for hen egg-white lysozyme paratope grafting ( Fig. 1a ), restricted randomization of the central 12 amino acids with a degenerate codon (DVN) that only encodes for 12 of the canonical 20 amino acids. As most encoded amino acids by DVN codon were described as abundant in natural CDRs and antigenic contacts [36] , we expected to improve the selection of high-affinity sdAbs. Moreover, these amino acids seem to be sufficient to generate high-affinity and specific minimalist synthetic binders [35, 36] . A library of $8.0 Â 10 9 clones was generated, cloned, and selected by phage display against a crucial-to-fusion, difficult-to-access, and well conserved sequence on HR1 (HR1 546-581(HXB2) ), named N36 [19] (Fig. S2 , http:// links.lww.com/QAD/A912). Apart from the cryptic nature of the entire HR1 region, N36 comprises residues of a particularly deep cavity, named hydrophobic pocket, described as highly conserved and a hot spot for neutralization of HIV-1 infection [19, 37] . Despite the therapeutic interest, this pocket is particularly difficult to target in an infection context because of its extreme concave conformation. As shown in Fig. 1b , we isolated five VLs with strong binding to HR1 from the 329 clones screened by ELISA. A further characterization of HR1 binding showed a dose-dependent binding for all five selected VLs ( Fig. 1c and Table S2 , http://links.lww.com/ QAD/A912). A competitive ELISA demonstrated that the five VLs showed a decreased binding to immobilized HR1 as the soluble HR1 amount increased, confirming VLs specificity of recognition ( Fig. 1c ).
To assess the antiviral activity of selected VLs, we performed a second screening ('functional screening') against HIV-1 NL4-3 -encoding the G547D mutation responsible for less susceptibility to T-20 fusion inhibitor [38] . From the five anti-HR1 VLs, F63 and D104 inhibited HIV-1 NL4-3 infectivity by $90% (Fig. 1d ) and were selected for further characterization of antiviral activity. Except for CDR1 of VL D103 that was not randomized, DNA sequencing analysis confirmed that all CDR1 and CDR3 sequences of the five anti-HR1 VLs were unique ( Fig. 1e ). F63 and D104 VLs were expressed and purified in high yield and used for further functional characterization ( Fig. S3 , http://links.lww.com/QAD/ A912).
Epitope mapping of antiviral VLs
Epitopes of F63 and D104 were mapped by ELISA, using a set of 10 overlapping synthetic peptides covering the template HR1 ( Fig. 2a ), and compared with the T-20 binding region. Both VLs exhibited similar target sequences within the central region of N36 with short overlap at the C-terminus of T-20 binding region ( Fig. 2b and c). F63 showed the strongest binding to peptide 5 (NH 2 -EAQQHMLQLTVWGIK-COOH), suggesting that it might contain its epitope ( Fig. 2b ). D104 showed similar binding to peptides 5 and 6 ( Fig. 2b) , indicating that its epitope is located within the overlapping sequence of 11 amino acids NH 2 -HMLQLTVWGIK-COOH ( Fig. 2a ).
Antiviral activity of VLs
The antiviral activity of VLs was first compared with T-20 peptide against the HIV-1 NL4-3 . T-20 also binds HR1 impairing the virus-cell fusion driven by HR1-HR2 interaction, an inhibition mechanism we reasoned to be similar to selected anti-HIV VLs. As shown in Fig. 3a , both F63 and D104 strongly inhibited HIV-1 NL4-3 infection in TZM-bl cells (IC 50 was 0.5 AE 0.2 nmol/l for F63 and 9.7 AE 5.4 nmol/l for D104). Remarkably, F63 was more active against HIV-1 NL4-3 than D104 and T-20 (IC 50 was 0.5 AE 0.2 nmol/l for F63 vs. 9.7 AE 5.4 nmol/l for D104 and 3.1 AE 1.9 nmol/l for T-20). As expected, the VL parental did not inhibit HIV-1 NL4-3 . F63 and D104 also strongly inhibited HIV-1 infection similarly to T-20 in Jurkat cells (IC 50 was 0.1 AE 0.01 nmol/l for F63, 0.6 AE 0.1 nmol/l for D104, and 0.1 AE 0.01 nmol/l for T-20; Fig. 3b ). No cytotoxicity was observed when either TZM-bl or Jurkat cells were incubated with the highest concentration of the VLs (Fig. S4 , http://links.lww.com/ QAD/A912). We also assessed F63 antiviral activity as a dimer. Surprisingly, F63 dimer did not inhibit HIV-1 NL4-3 infection (data not shown), which is probably related to steric restrictions in F63 epitope access.
We then asked whether F63 and D104 could inhibit cell-cell fusion between Env-positive cells (HeLa243env) and adjacent CD4-expressing cells (MAGI) [25] . Similar to T-20 and in contrast to VL parental , F63 and D104 impaired HeLa cell-cell fusion in a concentrationdependent manner (Fig. 3c ). Fusion between control HeLa273Denvwithout Env expression -and MAGI cells did not occur (data not shown). These results emphasize HIV-1 fusion as the target of F63 and D104.
To test the hypothesis that F63 and D104 were as active as T-20 toward clinically relevant HIV isolates, the IC 50 of VLs was evaluated against two HIV-1 and HIV-2 primary isolates in TZM-bl cells. HIV-1 primary isolates belong to distinct subtypes of the major HIV-1 group M, clade J (93AOHDC250) [26] and clade H (93AOCA251) [26] . HIV-2 primary isolates 03PTHCC12 and 10PTHSMNC [26] Fig. 4a and c) . This fact still supports F63 as a potent inhibitor of these two HIV-1 primary isolates. In contrast to T-20, F63 also inhibited the two HIV-2 primary isolates in the nanomolar range (IC 50 was 460 AE 19 nmol/l for F63 vs. 2855 AE 483 nmol/ l for T-20 for 03PTHCC12 isolate; IC 50 was 433 AE 38 nmol/l for F63 vs. 266 AE 25 nmol/l for T-20 for 10PTHSMNC isolate; Fig. 4b and d) . In contrast to F63, D104 did not inhibit either HIV-1 or HIV-2 primary isolates (data not shown). These results suggest that in addition to inhibition of HIV-1 non-B subtypes, F63 can be a potent inhibitor of HIV-2 isolates. We also tested the antiviral potency of F63 in peripheral blood mononuclear cells against a panel of HIV-1 primary isolates from the most prevalent subtypes B (developed countries) and C (developing countries). As shown in Table S3 , http://links.lww.com/QAD/A912, the IC 50 values obtained for F63 were similar to T-20 in the nanopicomolar range. These results indicate that F63 also potently inhibits isolates from the most prevalent HIV-1 subtypes in primary lymphocytes, with comparable activity to T-20.
Overall, F63 was as active as T-20 as judged by the IC 50 against all tested HIV isolates (no significant P value; Fig. 4e ). Moreover, F63 was not significantly less active than T-20 either for HIV-1 or HIV-2 primary isolates (no significant P value; data not shown). These results indicate that F63 presents an antiviral activity similar to T-20. To test F63 neutralizing activity against HIV-1 strains resistant to T-20, we evaluated the susceptibility of two HIV-1 variants displaying well defined mutations for T-20 resistance [38, 40] . HIV-1 variants resistant to T-20 derived from HIV-1 NL4-3 D36G (parental) susceptible to T-20 [38, 40] . F63 presented no fold increase of IC 50 for all tested HIV-1 variants resistant to T-20 relative to parental HIV-1 (IC 50 fold increase was 0.66 for NL4-3 (D36G) V38A/N42D; no significant P value and 0.70 for NL4-3 (D36G) V38A/N42T; no significant P value; Fig.  S5 , http://links.lww.com/QAD/A912). In contrast, T-20 IC 50 was reported to present a fold increase of approximately 3.94 Â 10 3 and 1.61 Â 10 4 for HIV-1 variants NL4-3 (D36G) V38A/N42D and V38A/N42T, respectively, comparing with the parental HIV-1 [6] . These data suggest that F63 could constitute an alternative in the treatment of patients infected with HIV-1 strains resistant to T-20.
F63 interaction with lipid membranes
As T-20 antiviral mechanism is associated with membrane interaction, we also evaluated the lipid-binding capacity of F63 against membrane model systems mimicking the major lipids of cellular membrane and cholesterol-rich viral envelope [41] . In the presence of lipid membranes, variations in the fluorescent residue emission are typically associated with protein-membrane interactions [42] . Taking advantage of the tryptophan residue (Trp; position 46 in F63 and 37 in VL parental Fig. 1e ), we performed partition experiments based on the VL quantum yield variations. Fluorescence emission from F63 Trp decreased with increasing lipid concentrations of the both membrane models tested ( Fig. 5a and b) . The K p values retrieved from data fitting with the partition formalism were in the same order of magnitude for viral envelope and cell membrane models (Table S4 , http://links.lww. com/QAD/A912). The K p correlates with the extent of protein interaction with the lipid membrane modelsratio between the concentration of a given molecule in two separate and immiscible phases. In contrast, we did not observe variations in the fluorescence emission of VL parental Trp (Fig. 5a and b) . These results suggest that , which are responsive to variations in membrane dipole potential, can also be exploited to study protein-membrane interactions [43] . Excitation spectra of di-8-ANEPPS inserted in both membrane models underwent a redshift to higher wavelengthsindication of a membrane dipole potential perturbationonly in the F63 presence ( Fig. 5c and d) . These observations complement the previous partition results and support the hypothesis that F63 has unique membrane-interacting properties, unlike VL parental . F63 also presented a binding affinity (K D ) of $8 nmol/l to N36 as determined by surface plasmon resonance (Table  S5 , http://links.lww.com/QAD/A912), establishing this VL as a high-affinity binder in the low nanomolar range.
Discussion
HIV entry inhibition is a key component of any antiviral therapeutic scheme leading to impairment of de novo infection. In this report, we selected a broad and potent HIV fusion inhibitor from a synthetic repertoire of VL domains. Several studies have shown that VLs tend to aggregate less [12] [13] [14] and present higher antigenbinding properties [44, 45] than VH domains. In this study, we went further relative to others [46, 47] and successfully selected a high-affinity VL with elongated CDRs. Our data suggest that the screening of libraries containing CDRs-elongated antibody formats result in the selection of cryptic epitope binders, mimicking the longer and more flexible CDRs found in camelids [48] .
Here, we took advantage of VLs reduced size to target a sterically restricted region on HR1 of gp41 (N36). Together with the corresponding HR2 region, N36 is sufficient to form the 6HB structure responsible for the HIV fusion [19] . Accordingly, a VL-N36 interaction would prevent the 6HB assembly, leading to HIV entry impairment. Epitope mapping of the most potent HIV inhibitors revealed two similar sequences within the N36 central region, previously described as part of a highly conserved cavity (hydrophobic pocket) essential for HR2 binding [19, 49] . Despite the location of D104 target region within the F63 target sequence, antiviral activity against HIV primary isolates was only observed with F63. Thus, our data seem to indicate that targeting of D104 epitope is insufficient for broad neutralization of HIV. Nevertheless, as D104 affinity was not determined, we cannot exclude that it may influence viral inhibition. On the other hand, F63 epitope represents a promising target with $60% conservation amongst HIV-1 subtypes and even HIV types ( Fig. S2 , http://links.lww.com/QAD/ A912). This predicted epitope is also distinct from the T-20 binding region that has a low genetic barrier to drug resistance, mainly the Gly-Ile-Val sequence (HR1 [36] [37] [38] ) [38, 50] , as reinforced by the observed F63 inhibition of T-20 resistant HIV-1 strains. Moreover, a substitution of a single residue on $70% of the F63 predicted epitope would lead to impaired or nonfunctional HIV-1 entry mutants as reported by Sen et al. [51] ( Fig. S2 , http://links.lww.com/QAD/A912). F63 epitope conservation and importance for HIV fusion together with the fact that this VL domain inhibited HIV-1 primary isolates from distinct subtypes similarly to T-20 and HIV-2 primary isolates highlight F63 potency and predict a high breadth for this inhibitor. Moreover, as T-20 has a limited activity on HIV-2 [6, 52] , F63 could constitute an alternative to the treatment of this HIV type.
The close proximity of gp41 to viral envelope and cellular membrane during HIV entry questions the role of membranes in gp41-targeting inhibitors mechanism. For example, T-20 shows considerable interaction with lipid membranes [20] . Also, broadly neutralizing antibodies 2F5 and 4E10 are capable of stable epitope binding through cross-reactive lipid interaction [53] . We have assessed F63 membrane interactions through fluorescence spectroscopy methodologies and identified its partition toward lipid membrane models. Interestingly, the VL parental was unable to interact with these models, suggesting that this property was acquired during CDRs randomization and is associated to CDR1 and/or CDR3. From a pharmacological standpoint, membranes interaction is a desirable property of an inhibitor mechanism [54] , enabling the establishment of local and transient reservoirs both in the viral envelope and cellular membrane. Furthermore, the F63 lack of a Fc immune-triggering domain avoids cross-reactivity with lipids, a significant drawback in 2F5 and 4E10 application [55] .
To our knowledge, this is the first report presenting a synthetic VL sdAb designed as a potent inhibitor of HIV infection. Other fusion inhibitors with an antiviral activity similar to F63 were already described [7, 56] . However, F63 combine the reduced molecular weight of small nonantibody inhibitors with the specificity and high-affinity of antibody paratopes and the excellent biophysical properties and versatility of antibody formats. Despite VHH antibody fragments were also identified as anti-HIV inhibitors [57] [58] [59] [60] [61] , these variable domains target gp120 and were not synthetically randomized, being derived from llama immunization. Owing to protease resistance and simplicity of sdAbs, F63 may also overcome major T-20 weaknesses, such as oral administration preclusion, high production cost, and short half-life [62, 63] . Additionally, F63 potency and biodistribution may be further improved by several strategies such as coupling of effector molecules (enzymes and cytotoxic drugs) and inhibitor targeting to the cholesterol-rich areas where HIV preferentially enters [64] , for example, through attachment of cholesterolbinding peptides.
To address the expected immunogenicity of a rabbit VL, we successfully humanized F63 by removing residues potentially recognized as T-cell epitopes (deimmunization) as described in Jones et al. [65] . Humanized F63 neutralized HIV-1 NL4-3 laboratory-adapted strain similarly to rabbit F63 and proved to be more stable than its rabbit homolog because of alanine substitution of unpaired cysteines performed along with F63 humanization (data not shown). It is conceivable that the rabbitconserved cysteine at position 91 -that forms an unusual disulfide bridge between variable and constant domains [66] -together with the cysteine selected in CDR1 sequence were major contributors to the insolubility of F63 during the purification process. Therefore, our library design strategy could benefit from the replacement of DVN by the NDT degenerate codon, which encodes fewer cysteine residues and does not yield stop codons.
In conclusion, we successfully developed a potent and broad fusion inhibitor of HIV-1 and HIV-2 infection using a VL sdAb as scaffold. We validated the selection of potent inhibitors based on a rational engineering strategy for synthetic library design. Our findings also encourage exploration of CDRs elongation for the design or improvement of next generation HIV inhibitors.
